Drug Trial Radar · NCT07817108
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18,000
Planned (sponsor's estimate)
Start
Jun 27, 2026
Primary completion
Oct 17, 2027
Study completion Oct 17, 2027
Sponsor
- Lead sponsor
- Suzhou Abogen Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Abogen Biosciences (Shanghai) Co., Ltd
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the vaccine efficacy, safety and immunogenicity of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
Conditions
- Varicella-zoster Virus
Interventions
ABO1108Biological
Formulation for injection
PlaceboDrug
0.9% sodium chloride (normal saline) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed herpes zoster incidence rate per person-year]Time frame: ≥30 days after receiving two doses of the study vaccine
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Shandong Center for Disease Control and Prevention
Jinan, China · Recruiting
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Nanning, China · Recruiting
Hebei Province Center for Disease Control and Prevention
Shijiazhuang, China · Recruiting
Zhejiang Center for Disease Control and Prevention
Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.